Neuroblastoma staging: Difference between revisions
No edit summary |
|||
Line 161: | Line 161: | ||
<div style="width: 20em; padding:0em;text-align:left"> | <div style="width: 20em; padding:0em;text-align:left"> | ||
* '''INSS stage 1'''<br> | * '''INSS stage 1'''<br> | ||
*'''Irrespective of age'''<br> | *'''Irrespective of [[age]]'''<br> | ||
*'''Irrespective of grade'''<br> | *'''Irrespective of grade'''<br> | ||
*'''Irrespective of molecular pathway'''</div>}} | *'''Irrespective of molecular pathway'''</div>}} | ||
Line 167: | Line 167: | ||
{{familytree | | | | | | C01 |-|+|-| B01 | | | | |C01=<div style="width: 20em; padding:0em;text-align:center">'''Low risk neuroblastoma patients (group 1)'''</div>|B01=<div style="width: 20em; padding:0em;text-align:left"> | {{familytree | | | | | | C01 |-|+|-| B01 | | | | |C01=<div style="width: 20em; padding:0em;text-align:center">'''Low risk neuroblastoma patients (group 1)'''</div>|B01=<div style="width: 20em; padding:0em;text-align:left"> | ||
*'''INSS stage 2A/2B (>50% resected)'''<br> | *'''INSS stage 2A/2B (>50% resected)'''<br> | ||
*'''Irrespective of age'''<br> | *'''Irrespective of [[age]]'''<br> | ||
*'''Irrespective of grade'''<br> | *'''Irrespective of grade'''<br> | ||
*'''''MYCN'' not amplified'''</div>}} | *'''''MYCN'' not amplified'''</div>}} | ||
Line 173: | Line 173: | ||
{{familytree | | | | | | | | | |`|-| C02 | | | | | | |C02=<div style="width: 20em; padding:0em;text-align:left"> | {{familytree | | | | | | | | | |`|-| C02 | | | | | | |C02=<div style="width: 20em; padding:0em;text-align:left"> | ||
*'''INNS stage 4S'''<br> | *'''INNS stage 4S'''<br> | ||
*'''<365 days of age'''<br> | *'''<365 days of [[age]]'''<br> | ||
*'''Favorable histology'''<br> | *'''Favorable [[histology]]'''<br> | ||
*'''DNA index >1'''<br> | *'''DNA index >1'''<br> | ||
*'''''MYCN'' not amplified'''</div>}} | *'''''MYCN'' not amplified'''</div>}} | ||
Line 183: | Line 183: | ||
<div style="width: 20em; padding:0em;text-align:left"> | <div style="width: 20em; padding:0em;text-align:left"> | ||
*'''INNS stage 2A/2B (<50% resected)'''<br> | *'''INNS stage 2A/2B (<50% resected)'''<br> | ||
*'''0-12 years of age'''<br> | *'''0-12 years of [[age]]'''<br> | ||
*'''Irrespective of grade'''<br> | *'''Irrespective of grade'''<br> | ||
*'''''MYCN'' not amplified'''</div>}} | *'''''MYCN'' not amplified'''</div>}} | ||
Line 189: | Line 189: | ||
{{familytree | | | | | | | | |)|-| B01 | | | | ||B01=<div style="width: 20em; padding:0em;text-align:left"> | {{familytree | | | | | | | | |)|-| B01 | | | | ||B01=<div style="width: 20em; padding:0em;text-align:left"> | ||
*'''INSS stage 3'''<br> | *'''INSS stage 3'''<br> | ||
*'''<365 days of age'''<br> | *'''<365 days of [[age]]'''<br> | ||
*'''Favorable histology'''<br> | *'''Favorable [[histology]]'''<br> | ||
*'''DNA index >1'''<br> | *'''DNA index >1'''<br> | ||
*'''''MYCN'' not amplified'''</div>}} | *'''''MYCN'' not amplified'''</div>}} | ||
Line 196: | Line 196: | ||
{{familytree | | | | | | | | |)|-| C02 | | | | | | |C02=<div style="width: 20em; padding:0em;text-align:left"> | {{familytree | | | | | | | | |)|-| C02 | | | | | | |C02=<div style="width: 20em; padding:0em;text-align:left"> | ||
*'''INNS stage 3'''<br> | *'''INNS stage 3'''<br> | ||
*'''1-12 years of age'''<br> | *'''1-12 years of [[age]]'''<br> | ||
*'''Favorable histology'''<br> | *'''Favorable [[histology]]'''<br> | ||
*'''''MYCN'' not amplified'''</div>}} | *'''''MYCN'' not amplified'''</div>}} | ||
{{familytree | | | | | | | | |!| | | | | | | | | | | | | | | | | }} | {{familytree | | | | | | | | |!| | | | | | | | | | | | | | | | | }} | ||
{{familytree | | | | | | | | |`|-| C02 | | | | | | |C02=<div style="width: 20em; padding:0em;text-align:left"> | {{familytree | | | | | | | | |`|-| C02 | | | | | | |C02=<div style="width: 20em; padding:0em;text-align:left"> | ||
*'''Symptomatic INNS stage 4S'''<br> | *'''Symptomatic INNS stage 4S'''<br> | ||
*'''<365 days of age'''<br> | *'''<365 days of [[age]]'''<br> | ||
*'''Favorable histology'''<br> | *'''Favorable [[histology]]'''<br> | ||
*'''DNA index >1'''<br> | *'''DNA index >1'''<br> | ||
*'''''MYCN'' not amplified'''</div>}} | *'''''MYCN'' not amplified'''</div>}} | ||
Line 212: | Line 212: | ||
<div style="width: 20em; padding:0em;text-align:left"> | <div style="width: 20em; padding:0em;text-align:left"> | ||
* '''INSS stage 3'''<br> | * '''INSS stage 3'''<br> | ||
*'''<365 days of age'''<br> | *'''<365 days of [[age]]'''<br> | ||
*'''Unfavorable histology'''<br> | *'''Unfavorable [[histology]]'''<br> | ||
*'''DNA index=1'''<br> | *'''DNA index=1'''<br> | ||
*'''''MYCN'' not amplified'''</div>}} | *'''''MYCN'' not amplified'''</div>}} | ||
Line 219: | Line 219: | ||
{{familytree | | | | | | C01 |-|+|-| B01 | | | | |C01=<div style="width: 20em; padding:0em;text-align:center">'''Intermediate risk neuroblastoma patients (group 3)'''</div>|B01=<div style="width: 20em; padding:0em;text-align:left"> | {{familytree | | | | | | C01 |-|+|-| B01 | | | | |C01=<div style="width: 20em; padding:0em;text-align:center">'''Intermediate risk neuroblastoma patients (group 3)'''</div>|B01=<div style="width: 20em; padding:0em;text-align:left"> | ||
*'''INSS stage 4'''<br> | *'''INSS stage 4'''<br> | ||
*'''<365 days of age'''<br> | *'''<365 days of [[age]]'''<br> | ||
*'''Favorable histology'''<br> | *'''Favorable [[histology]]'''<br> | ||
*'''DNA index >1'''<br> | *'''DNA index >1'''<br> | ||
*'''''MYCN'' not amplified'''</div>}} | *'''''MYCN'' not amplified'''</div>}} | ||
Line 226: | Line 226: | ||
{{familytree | | | | | | | | | |`|-| C02 | | | | | | |C02=<div style="width: 20em; padding:0em;text-align:left"> | {{familytree | | | | | | | | | |`|-| C02 | | | | | | |C02=<div style="width: 20em; padding:0em;text-align:left"> | ||
*'''INNS stage 4S'''<br> | *'''INNS stage 4S'''<br> | ||
*'''<365 days of age'''<br> | *'''<365 days of [[age]]'''<br> | ||
*'''Unfavorable histology'''<br> | *'''Unfavorable [[histology]]'''<br> | ||
*'''DNA index=1'''<br> | *'''DNA index=1'''<br> | ||
*'''''MYCN'' not amplified'''</div>}} | *'''''MYCN'' not amplified'''</div>}} | ||
Line 236: | Line 236: | ||
<div style="width: 20em; padding:0em;text-align:left"> | <div style="width: 20em; padding:0em;text-align:left"> | ||
* '''INSS stage 4'''<br> | * '''INSS stage 4'''<br> | ||
*'''<365 days of age'''<br> | *'''<365 days of [[age]]'''<br> | ||
*'''Unfavorable histology'''<br> | *'''Unfavorable histology'''<br> | ||
*'''DNA index=1'''<br> | *'''[[DNA]] index=1'''<br> | ||
*'''''MYCN'' not amplified'''</div>}} | *'''''MYCN'' not amplified'''</div>}} | ||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | }} | {{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | }} | ||
{{familytree | | | | | | C01 |-|+|-| B01 | | | | |C01=<div style="width: 20em; padding:0em;text-align:center">'''Intermediate risk neuroblastoma patients (group 4)'''</div>|B01=<div style="width: 20em; padding:0em;text-align:left"> | {{familytree | | | | | | C01 |-|+|-| B01 | | | | |C01=<div style="width: 20em; padding:0em;text-align:center">'''Intermediate risk neuroblastoma patients (group 4)'''</div>|B01=<div style="width: 20em; padding:0em;text-align:left"> | ||
*'''INSS stage 3'''<br> | *'''INSS stage 3'''<br> | ||
*'''365-547 days of age'''<br> | *'''365-547 days of [[age]]'''<br> | ||
*'''Unfavorable histology'''<br> | *'''Unfavorable [[histology]]'''<br> | ||
*'''''MYCN'' not amplified'''</div>}} | *'''''MYCN'' not amplified'''</div>}} | ||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | }} | {{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | }} | ||
{{familytree | | | | | | | | | |`|-| C02 | | | | | | |C02=<div style="width: 20em; padding:0em;text-align:left"> | {{familytree | | | | | | | | | |`|-| C02 | | | | | | |C02=<div style="width: 20em; padding:0em;text-align:left"> | ||
*'''INNS stage 4'''<br> | *'''INNS stage 4'''<br> | ||
*'''365-547 days of age'''<br> | *'''365-547 days of [[age]]'''<br> | ||
*'''Favorable histology'''<br> | *'''Favorable [[histology]]'''<br> | ||
*'''DNA index>1'''<br> | *'''[[DNA]] index>1'''<br> | ||
*'''''MYCN'' not amplified'''</div>}} | *'''''MYCN'' not amplified'''</div>}} | ||
{{familytree/end}} | {{familytree/end}} | ||
Line 259: | Line 259: | ||
<div style="width: 20em; padding:0em;text-align:left"> | <div style="width: 20em; padding:0em;text-align:left"> | ||
*'''INNS stage 2A/2B, Stage 3 , Stage 4 or Stage 4S'''<br> | *'''INNS stage 2A/2B, Stage 3 , Stage 4 or Stage 4S'''<br> | ||
*'''Irrespective of age'''<br> | *'''Irrespective of [[age]]'''<br> | ||
*'''Irrespective of grade'''<br> | *'''Irrespective of grade'''<br> | ||
*'''''MYCN'' amplified'''</div>}} | *'''''MYCN'' amplified'''</div>}} | ||
Line 265: | Line 265: | ||
{{familytree | | | | | | | | |)|-| B01 | | | | ||B01=<div style="width: 20em; padding:0em;text-align:left"> | {{familytree | | | | | | | | |)|-| B01 | | | | ||B01=<div style="width: 20em; padding:0em;text-align:left"> | ||
*'''INSS stage 3'''<br> | *'''INSS stage 3'''<br> | ||
*'''>547 days of age'''<br> | *'''>547 days of [[age]]'''<br> | ||
*'''Unfavorable histology'''<br> | *'''Unfavorable [[histology]]'''<br> | ||
*'''''MYCN'' not amplified'''</div>}} | *'''''MYCN'' not amplified'''</div>}} | ||
{{familytree | | | | | C01 |-|(| | | | | |C01=<div style="width: 20em; padding:1em;text-align:center">'''High risk neuroblastoma patients (group 5)'''</div> | | | | | | | | | | | | }} | {{familytree | | | | | C01 |-|(| | | | | |C01=<div style="width: 20em; padding:1em;text-align:center">'''High risk neuroblastoma [[patients]] (group 5)'''</div> | | | | | | | | | | | | }} | ||
{{familytree | | | | | | | | |)|-| C02 | | | | | | |C02=<div style="width: 20em; padding:0em;text-align:left"> | {{familytree | | | | | | | | |)|-| C02 | | | | | | |C02=<div style="width: 20em; padding:0em;text-align:left"> | ||
*'''INNS stage 4'''<br> | *'''INNS stage 4'''<br> | ||
*'''365-547 days of age'''<br> | *'''365-547 days of [[age]]'''<br> | ||
*'''Unfavorable histology'''<br> | *'''Unfavorable [[histology]]'''<br> | ||
*'''DNA index=1'''<br> | *'''[[DNA]] index=1'''<br> | ||
*'''''MYCN'' not amplified'''</div>}} | *'''''MYCN'' not amplified'''</div>}} | ||
{{familytree | | | | | | | | |!| | | | | | | | | | | | | | | | | }} | {{familytree | | | | | | | | |!| | | | | | | | | | | | | | | | | }} | ||
{{familytree | | | | | | | | |`|-| C02 | | | | | | |C02=<div style="width: 20em; padding:0em;text-align:left"> | {{familytree | | | | | | | | |`|-| C02 | | | | | | |C02=<div style="width: 20em; padding:0em;text-align:left"> | ||
*'''INNS stage 4'''<br> | *'''INNS stage 4'''<br> | ||
*'''>547 days of age'''<br> | *'''>547 days of [[age]]'''<br> | ||
*'''Irrespective grade'''<br> | *'''Irrespective grade'''<br> | ||
*'''Irrespective ''MYCN'' amplification state'''</div>}} | *'''Irrespective ''MYCN'' [[amplification]] state'''</div>}} | ||
{{familytree/end}} | {{familytree/end}} | ||
Latest revision as of 15:15, 4 March 2019
Neuroblastoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Neuroblastoma staging On the Web |
American Roentgen Ray Society Images of Neuroblastoma staging |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2] Zahir Ali Shaikh, MD[3]
Overview
According to the conventional International Neuroblastoma Staging System (INSS), there are 6 stages of neuroblastoma based on the tumor size, lymph node involvement, and presence of metastasis. However, according to a newly proposed International Neuroblastoma Risk Group Staging System (INRGSS), there are four stages of neuroblastoma based on the extent of dissemination and image findings. Neuroblastoma patients are risk stratified according to the Children Oncology Group (COG) risk stratification system into a low risk group, an intermediate risk group, and a high risk group based on the tumor INSS stage, the patient's age, tumor grade, and the amplification of MYCN gene.
Neuroblastoma Staging
International Neuroblastoma Staging System (INSS)
- According to the conventional International Neuroblastoma Staging System (INSS), there are 6 stages of neuroblastoma based on the tumor size, lymph node involvement, and presence of metastasis.[1][2][3][4][5]
Stage | Description |
Stage 1 |
|
Stage 2A |
|
Stage 2B |
|
Stage 3 |
|
Stage 4 |
|
Stage 4S |
|
International Neuroblastoma Risk Group Staging System (INRGSS)
According to a newly proposed International Neuroblastoma Risk Group Staging System (INRGSS), there are four stages of neuroblastoma based on the extent of dissemination and image findings.[2][6][7][8]
Stage | Description |
Stage L1 |
|
Stage L2 |
|
Stage M | |
Stage MS |
|
Risk Stratification
Children's Oncology Group Risk Stratification
- Children Oncology Group (COG) risk stratification system determines the protocol of management used for neuroblastoma patients.[9]
- Neuroblastoma patients are risk stratified into a low risk group, intermediate risk groups, and a high risk group based on the INSS stage, the patient's age, histological grade, and the amplification of MYCN gene.[1][2][10]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Low risk neuroblastoma patients (group 1) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Intermediate risk neuroblastoma patients (group 2) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Intermediate risk neuroblastoma patients (group 3) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intermediate risk neuroblastoma patients (group 4) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
High risk neuroblastoma patients (group 5) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
References
- ↑ 1.0 1.1 Davidoff AM (2012). "Neuroblastoma". Semin Pediatr Surg. 21 (1): 2–14. doi:10.1053/j.sempedsurg.2011.10.009. PMC 3261589. PMID 22248965.
- ↑ 2.0 2.1 2.2 Colon NC, Chung DH (2011). "Neuroblastoma". Adv Pediatr. 58 (1): 297–311. doi:10.1016/j.yapd.2011.03.011. PMC 3668791. PMID 21736987.
- ↑ H. Shimada, S. Umehara, Y. Monobe, Y. Hachitanda, A. Nakagawa, S. Goto, R. B. Gerbing, D. O. Stram, J. N. Lukens & K. K. Matthay (2001). "International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group". Cancer. 92 (9): 2451–2461. PMID 11745303. Unknown parameter
|month=
ignored (help) - ↑ D. de Sa (2000). "Neuroblastoma classification". Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society. 3 (5): 506–507. PMID 10890940. Unknown parameter
|month=
ignored (help) - ↑ S. Goto, S. Umehara, R. B. Gerbing, D. O. Stram, G. M. Brodeur, R. C. Seeger, J. N. Lukens, K. K. Matthay & H. Shimada (2001). "Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group". Cancer. 92 (10): 2699–2708. PMID 11745206. Unknown parameter
|month=
ignored (help) - ↑ Susan L. Cohn, Andrew D. J. Pearson, Wendy B. London, Tom Monclair, Peter F. Ambros, Garrett M. Brodeur, Andreas Faldum, Barbara Hero, Tomoko Iehara, David Machin, Veronique Mosseri, Thorsten Simon, Alberto Garaventa, Victoria Castel & Katherine K. Matthay (2009). "The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27 (2): 289–297. doi:10.1200/JCO.2008.16.6785. PMID 19047291. Unknown parameter
|month=
ignored (help) - ↑ Tom Monclair, Garrett M. Brodeur, Peter F. Ambros, Herve J. Brisse, Giovanni Cecchetto, Keith Holmes, Michio Kaneko, Wendy B. London, Katherine K. Matthay, Jed G. Nuchtern, Dietrich von Schweinitz, Thorsten Simon, Susan L. Cohn & Andrew D. J. Pearson (2009). "The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27 (2): 298–303. doi:10.1200/JCO.2008.16.6876. PMID 19047290. Unknown parameter
|month=
ignored (help) - ↑ Sidharth Mahapatra & Kishore B.. Challagundla (2018). "Cancer, Neuroblastoma". PMID 28846355. Unknown parameter
|month=
ignored (help) - ↑ Neuroblastoma treatment–for health professionals. National Cancer Institute (2015) http://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq#section/_1 Accessed on October, 8 2015
- ↑ Nadja C. Colon & Dai H. Chung (2011). "Neuroblastoma". Advances in pediatrics. 58 (1): 297–311. doi:10.1016/j.yapd.2011.03.011. PMID 21736987.